Sugi Predict

Sugi Predict / Compounds / SCHEMBL932013

SCHEMBL932013

SCHEMBL932013

C=Cc1ccc(C(C)=O)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNJ1 P48048 1/20 0.42
▸ L3MBTL1 Q9Y468 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ KMT2A Q03164 1/20 0.41
▸ TSHR P16473 1/20 0.37
▸ KDM4C Q9H3R0 1/20 0.37
▸ LMNA P02545 3/20 0.37
▸ MAPT P10636 3/20 0.37
▸ POLB P06746 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ HPGD P15428 2/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ HCAR3 P49019 1/20 0.36
▸ P4HA1 P13674 2/20 0.35
▸ P4HTM Q9NXG6 2/20 0.35
▸ HSD17B1 P14061 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ RARA P10276 1/20 0.35
▸ RARB P10826 1/20 0.35
▸ RARG P13631 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31003291 1.00 KCNJ1 (0.42) KCNJ1L3MBTL1KDM4EKMT2ATSHR
SCHEMBL845436 0.82 P4HA1 (0.55) L3MBTL1KDM4ETSHRMAPTHPGD
SCHEMBL15581120 0.82 KCNJ1 (0.44) KCNJ1L3MBTL1KDM4EKMT2ATSHR
SCHEMBL29956704 0.82 KCNJ1 (0.44) KCNJ1L3MBTL1KDM4EKMT2ATSHR
SCHEMBL23643157 0.81 KCNJ1 (0.42) KCNJ1L3MBTL1KDM4EKMT2ATSHR
SCHEMBL29915751 0.81 KDM4E (0.64) L3MBTL1KDM4ESMN1; SMN2
SCHEMBL29923668 0.81 KDM4E (0.64) L3MBTL1KDM4ESMN1; SMN2
SCHEMBL846377 0.80 MAPK1 (0.59) L3MBTL1KDM4EKMT2ATSHRMAPT
SCHEMBL31601570 0.80 MAPK1 (0.59) L3MBTL1KDM4EKMT2ATSHRMAPT
SCHEMBL27876298 0.80 KDM4E (0.46) L3MBTL1KDM4EKMT2AKDM4CMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9212148-B2 Functionalizing reagents and their uses GLYTHERA LIMITED (GB) 2015-12-15 — — US disclosed
US-20150297596-A1 ISOXAZOLINES AS THERAPEUTIC AGENTS ABBVIE INC. (US) 2015-10-22 — — US disclosed
US-20150297596-A1 ISOXAZOLINES AS THERAPEUTIC AGENTS ABBVIE INC. (US) 2015-10-22 — — US disclosed
US-9029409-B2 Isoxazolines as therapeutic agents ABBVIE INC. (US) 2015-05-12 — — US disclosed
US-9029409-B2 Isoxazolines as therapeutic agents ABBVIE INC. (US) 2015-05-12 — — US disclosed
US-20140364586-A1 FUNCTIONALIZING REAGENTS AND THEIR USES Iksuda Therapeutics Limited (GB) 2014-12-11 — — US disclosed
US-8859534-B2 2-carboxamide-7-piperazinyl-benzofuran derivatives Acturum Life Science AB (SE) 2014-10-14 — — US disclosed
US-8859534-B2 2-carboxamide-7-piperazinyl-benzofuran derivatives Acturum Life Science AB (SE) 2014-10-14 — — US disclosed
US-8859534-B2 2-carboxamide-7-piperazinyl-benzofuran derivatives Acturum Life Science AB (SE) 2014-10-14 — — US disclosed
US-8785595-B2 Functionalising reagents and their uses GLYTHERA LIMITED (GB) 2014-07-22 — — US disclosed
US-20130023526-A1 Isoxazolines as Therapeutic Agents ABBOTT LABORATORIES (US) 2013-01-24 — — US disclosed
US-20130023526-A1 Isoxazolines as Therapeutic Agents ABBOTT LABORATORIES (US) 2013-01-24 — — US disclosed
WO-2012151158-A1 ISOXAZOLINES AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2012-11-08 — — WO disclosed
EP-2448934-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 AstraZeneca AB (SE) 2012-05-09 — — EP disclosed
US-20120101254-A1 FUNCTIONALISING REAGENTS AND THEIR USES Iksuda Therapeutics Limited (GB) 2012-04-26 — — US disclosed
WO-2011002405-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 ASTRAZENECA AB (SE) 2011-01-06 — — WO disclosed
WO-2011002405-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 ASTRAZENECA AB (SE) 2011-01-06 — — WO disclosed
US-20100331341-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 ASTRAZENECA AB (SE) 2010-12-30 — — US disclosed
US-20100331341-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 ASTRAZENECA AB (SE) 2010-12-30 — — US disclosed
US-20100331341-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 ASTRAZENECA AB (SE) 2010-12-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297596-A1 ISOXAZOLINES AS THERAPEUTIC AGENTS CYP3A7, CYP11B2, CYP11B1 KCNJ1 81/4885L3MBTL1 4821/4885KDM4E 3888/4885
US-20120101254-A1 FUNCTIONALISING REAGENTS AND THEIR USES VNN1, FGB, LNPEP KCNJ1 4626/4885L3MBTL1 2965/4885KDM4E 4441/4885
US-20130023526-A1 Isoxazolines as Therapeutic Agents CYP3A7, CYP11B2, CYP11B1 KCNJ1 81/4885L3MBTL1 4821/4885KDM4E 3888/4885
US-20100331341-A1 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 C1R, HTR4, HTR2C KCNJ1 1963/4885L3MBTL1 2021/4885KDM4E 789/4885
US-20140364586-A1 FUNCTIONALIZING REAGENTS AND THEIR USES VNN1, LNPEP, DNPEP KCNJ1 4721/4885L3MBTL1 3206/4885KDM4E 4515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.